Movement Alert｜PegBio Rises 8.42% in Regular Trading, Rani Therapeutics Oral Delivery Partnership Continues to Fuel Market Enthusiasm

Market Focus07-13 09:46

On July 13, PegBio (02565.HK) rose 8.42% in regular trading, trading at HKD 7.29/share, with turnover of HKD 108 million, extending the strong rally momentum from the previous Friday.

The sustained upside is driven by the memorandum of understanding signed on July 8 between PegBio and Nasdaq-listed Rani Therapeutics. Under the three-year agreement, the two companies will leverage Rani's proprietary RaniPill oral biologics delivery platform to conduct oral formulation screening and preclinical development for multiple innovative candidates in PegBio's obesity and metabolic disease pipeline. The parties also plan to explore cooperation in R&D, manufacturing, and commercialization of related products outside China. The collaboration adds a next-generation oral dosage form and overseas development pathway to PegBio's metabolic pipeline, with market sentiment continuing to build following the initial 35%+ surge on July 10 when the deal was first announced.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184828201?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184828201","market":"us","top_or_hot":-1,"title":"Movement Alert｜PegBio Rises 8.42% in Regular Trading, Rani Therapeutics Oral Delivery Partnership Continues to Fuel Market Enthusiasm","media":"Market Focus","content":"<p><p>On July 13, PegBio (02565.HK) rose 8.42% in regular trading, trading at HKD 7.29/share, with turnover of HKD 108 million, extending the strong rally momentum from the previous Friday.</p><p>The sustained upside is driven by the memorandum of understanding signed on July 8 between PegBio and Nasdaq-listed Rani Therapeutics. Under the three-year agreement, the two companies will leverage Rani's proprietary RaniPill oral biologics delivery platform to conduct oral formulation screening and preclinical development for multiple innovative candidates in PegBio's obesity and metabolic disease pipeline. The parties also plan to explore cooperation in R&D, manufacturing, and commercialization of related products outside China. The collaboration adds a next-generation oral dosage form and overseas development pathway to PegBio's metabolic pipeline, with market sentiment continuing to build following the initial 35%+ surge on July 10 when the deal was first announced.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PegBio Rises 8.42% in Regular Trading, Rani Therapeutics Oral Delivery Partnership Continues to Fuel Market Enthusiasm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PegBio Rises 8.42% in Regular Trading, Rani Therapeutics Oral Delivery Partnership Continues to Fuel Market Enthusiasm\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-13 09:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 13, PegBio (02565.HK) rose 8.42% in regular trading, trading at HKD 7.29/share, with turnover of HKD 108 million, extending the strong rally momentum from the previous Friday.</p><p>The sustained upside is driven by the memorandum of understanding signed on July 8 between PegBio and Nasdaq-listed Rani Therapeutics. Under the three-year agreement, the two companies will leverage Rani's proprietary RaniPill oral biologics delivery platform to conduct oral formulation screening and preclinical development for multiple innovative candidates in PegBio's obesity and metabolic disease pipeline. The parties also plan to explore cooperation in R&D, manufacturing, and commercialization of related products outside China. The collaboration adds a next-generation oral dosage form and overseas development pathway to PegBio's metabolic pipeline, with market sentiment continuing to build following the initial 35%+ surge on July 10 when the deal was first announced.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1184828201","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184828201","pubTimestamp":1783907175,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 13, PegBio (02565.HK) rose 8.42% in regular trading, trading at HKD 7.29/share, with turnover of HKD 108 million, extending the strong rally momentum from the previous Friday.The sustained...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"走势提醒|PegBio 常规交易上涨 8.42%，Rani Therapeutics 口服给药合作伙伴关系继续激发市场热情","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"On July 13, PegBio (02565.HK) rose 8.42% in regular trading, trading at HKD 7.29/share, with turnover of HKD 108 million, extending the strong rally momentum from the previous Friday.The sustained upside is driven by the memorandum of understanding signed on July 8 between PegBio and Nasdaq-listed Rani Therapeutics. Under the three-year agreement, the two companies will leverage Rani's proprietary RaniPill oral biologics delivery platform to conduct oral formulation screening and preclinical development for multiple innovative candidates in PegBio's obesity and metabolic disease pipeline. The parties also plan to explore cooperation in R&D, manufacturing, and commercialization of related products outside China. The collaboration adds a next-generation oral dosage form and overseas development pathway to PegBio's metabolic pipeline, with market sentiment continuing to build following the initial 35%+ surge on July 10 when the deal was first announced.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184828201","isCrawlerRequest":true}